William Grossman insider trades: enGene Therapeutics (ENGN) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where William reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | ENGN | ↑ Buy | 5,102 | $1.97 | $10K | Direct | Sep 24, 2026 (2d) |
| Jun 17, 2021 | RCUS | ↓ Sell | 7,065 | $23.89 | $169K | Direct | Jun 21, 2021 (4d) |
| Apr 23, 2021 | RCUS | ↓ Sell | 4,133 | $31.37 | $130K | Direct | Apr 26, 2021 (3d) |
| Mar 16, 2021 | RCUS | ↓ Sell | 2,127 | $35.03 | $75K | Direct | Mar 18, 2021 (2d) |
| Dec 16, 2020 | RCUS | ↓ Sell | 2,117 | $31.35 | $66K | Direct | Dec 18, 2020 (2d) |
| Jul 31, 2020 | RCUS | ↑ Buy | 200 | $19.72 | $4K | Direct | Aug 4, 2020 (4d) |
| Oct 14, 2019 | RCUS | ↑ Buy | 400 | $8.00 | $3K | Direct | Oct 15, 2019 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About William Grossman's insider trades
William Grossman is Interim Chief Medical Officer at enGene Therapeutics (ENGN). Since Oct 14, 2019, William has reported 3 open-market purchases worth $17K and 4 sales worth $439K on SEC Form 4. In the last 12 months: 1 buy ($10K).
Their filings also include grants and awards (13 filings), shares returned to the company (2 filings), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ENGN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.